<DOC>
	<DOC>NCT00093171</DOC>
	<brief_summary>The primary objective of this clinical research study is to assess the safety and efficacy of rFIX for a minimum of 6 months in previously treated patients (PTPs) with hemophilia B (FIX:C ≤2%) during standard-of-care treatment (on-demand, prophylaxis, and through major and minor surgical procedures).</brief_summary>
	<brief_title>Study Evaluating rFIX; BeneFIX® in Hemophilia B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Hemophilia B (FIX:C less than 2%) Previous treatment of at least 150 exposure days using any FIX product 12 years of age and older The patient has a currently detectable factor IX inhibitor or a history of inhibitors. (A family history of inhibitors will not exclude the patient) Known hypersensitivity to protein pharmaceuticals or agents related to the test article, e.g. hamster proteins Patient has a genetic coagulation disorder other than hemophilia B</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>